Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Mark R. Litzow, Kimberly J. Henderson, Scott A. Van Wier, Greg J. Ahmann, Rafael Fonseca

Research output: Contribution to journalArticle

284 Scopus citations

Abstract

Fluorescence in situ hybridization (FISH) is more sensitive than conventional cytogenetics for recognizing chromosomal changes. Several FISH-detected abnormalities have been associated with inferior prognosis, including deletion of chromosomes 17 and 13 (Δ13) and t(4;14)(p16.3;q32). We analyzed the prognostic value of FISH testing in 238 patients who received high-dose therapy between January 1990 and September 2001. All patients had pretransplantation cytoplasmic immunoglobulin FISH done on cytospin slides from bone marrow aspirates for t(11;14), t(4;14), and -17(p13.1) (TP53). Time to progression and overall survival were significantly shorter for patients with t(4;14) and those with -17(p13.1) but were not affected by t(11;14). Overall survival was significantly shorter for patients with both t(4;14) and Δ13 abnormalities than for those with Δ13 alone (26.8 vs 18.8 months). In a multivariable analysis of the effect of Δ13 and t(4;14), the risk ratio for t(4;14) was greater than for Δ13 (2.6 vs 1.5). For high-dose therapy patients, -17(p13) and t(4;14) have clinical importance for estimating time to progression and overall survival. The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)2837-2840
Number of pages4
JournalBlood
Volume106
Issue number8
DOIs
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy'. Together they form a unique fingerprint.

  • Cite this